Cargando…
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
BACKGROUND: von Hippel-Lindau disease (VHL) is a multisystem cancer syndrome caused by mutations in the VHL gene. Retinal hemangioblastoma is one of the most common tumours, and when it appears near the optic nerve, its treatment is challenging and risky. To date, no treatment has proven effective i...
Autores principales: | González-Rodríguez, Beatriz, Villar Gómez de las Heras, Karina, Aguirre, Daniel T, Rodríguez-Padial, Luis, Albiñana, Virginia, Recio-Poveda, Lucía, Cuesta, Angel M, Botella, Luisa Mª, Jiménez-Escribano, Rosa María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557078/ https://www.ncbi.nlm.nih.gov/pubmed/31245608 http://dx.doi.org/10.1136/bmjophth-2018-000203 |
Ejemplares similares
-
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
por: Albiñana, Virginia, et al.
Publicado: (2017) -
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients
por: Albiñana, Virginia, et al.
Publicado: (2015) -
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
por: Cuesta, A. M., et al.
Publicado: (2019) -
The Endothelial Landscape and Its Role in Von Hippel–Lindau Disease
por: de Rojas-P, Isabel, et al.
Publicado: (2021) -
Resection of von Hippel Lindau Related Brainstem Hemangioblastoma
por: Maggio, Dominic, et al.
Publicado: (2019)